Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation - Signal Transduction ... Signal Transduction and Targeted Therapy - Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors...

Phase II trial shows #KRASG12CInhibitor #Garsorasib, alone or with #cetuximab, delivers promising efficacy and manageable safety in heavily pretreated KRAS G12C–mutated #ColorectalCancer patients. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...